Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 8.77
(0.69%)
CNY 8.77
(0.69%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.67 Billion CNY | -60.13% |
| 2022 | 4.19 Billion CNY | 136.14% |
| 2021 | 1.77 Billion CNY | 43.62% |
| 2020 | 1.23 Billion CNY | 7.34% |
| 2019 | 1.15 Billion CNY | 9.57% |
| 2018 | 1.05 Billion CNY | 14.03% |
| 2017 | 923.23 Million CNY | 14.74% |
| 2016 | 804.64 Million CNY | 32.24% |
| 2015 | 608.47 Million CNY | 12.46% |
| 2014 | 541.03 Million CNY | 16.93% |
| 2013 | 462.69 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 450.4 Million CNY | 3.2% |
| 2024 Q3 | 429.21 Million CNY | -4.13% |
| 2024 Q1 | 436.44 Million CNY | 7.9% |
| 2023 Q2 | 425.32 Million CNY | 3.09% |
| 2023 Q3 | 431.96 Million CNY | 1.56% |
| 2023 FY | 1.67 Billion CNY | -60.13% |
| 2023 Q4 | 404.49 Million CNY | -6.36% |
| 2023 Q1 | 412.58 Million CNY | -62.16% |
| 2022 Q2 | 1.23 Billion CNY | 48.96% |
| 2022 Q1 | 827.68 Million CNY | 64.31% |
| 2022 FY | 4.19 Billion CNY | 136.14% |
| 2022 Q4 | 1.09 Billion CNY | 4.04% |
| 2022 Q3 | 1.04 Billion CNY | -14.99% |
| 2021 Q3 | 503.29 Million CNY | 21.31% |
| 2021 Q4 | 503.74 Million CNY | 0.09% |
| 2021 Q1 | 356.39 Million CNY | -4.83% |
| 2021 Q2 | 414.89 Million CNY | 16.41% |
| 2021 FY | 1.77 Billion CNY | 43.62% |
| 2020 Q4 | 374.46 Million CNY | 3.1% |
| 2020 FY | 1.23 Billion CNY | 7.34% |
| 2020 Q3 | 363.2 Million CNY | 6.44% |
| 2020 Q2 | 341.23 Million CNY | 114.22% |
| 2020 Q1 | 159.28 Million CNY | -51.06% |
| 2019 FY | 1.15 Billion CNY | 9.57% |
| 2019 Q4 | 325.49 Million CNY | 0.0% |
| 2018 FY | 1.05 Billion CNY | 14.03% |
| 2017 Q1 | 241.29 Million CNY | -1.73% |
| 2017 Q2 | 241.29 Million CNY | 0.0% |
| 2017 FY | 923.23 Million CNY | 14.74% |
| 2016 Q3 | 245.55 Million CNY | 56.63% |
| 2016 Q4 | 245.55 Million CNY | 0.0% |
| 2016 FY | 804.64 Million CNY | 32.24% |
| 2016 Q1 | 156.77 Million CNY | -15.43% |
| 2016 Q2 | 156.77 Million CNY | -0.0% |
| 2015 FY | 608.47 Million CNY | 12.46% |
| 2015 Q1 | 118.86 Million CNY | 0.0% |
| 2015 Q3 | 185.36 Million CNY | 55.95% |
| 2015 Q4 | 185.36 Million CNY | 0.0% |
| 2015 Q2 | 118.86 Million CNY | 0.0% |
| 2014 FY | 541.03 Million CNY | 16.93% |
| 2013 FY | 462.69 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 87.512% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 77.324% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -22.815% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | 3.862% |
| Medicalsystem Biotechnology Co., Ltd. | 1.88 Billion CNY | 11.215% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 42.179% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | 39.442% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -51.601% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 61.506% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -61.178% |